Transcode therapeutics stock.

TransCode Therapeutics Announces 1-for-20 Reverse Stock Split BOSTON, May 22, 2023 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors approved a 1-for-20 reverse stock ...

Transcode therapeutics stock. Things To Know About Transcode therapeutics stock.

Price Target. The average one-year price target for RNAZ / TransCode Therapeutics Inc is $12.24. The forecasts range from a low of $12.12 to a high of $12.6. A ...InvestorPlace - Stock Market News, Stock Advice & Trading Tips. TransCode Therapeutics (NASDAQ:RNAZ) stock is taking a beating on Friday after the oncology company announced plans for a public ...With TransCode Therapeutics delivering positive pre-clinical results for its brain tumor candidate, RNAZ stock soared on the implications.More From InvestorPlace Musk’s “Project Omega” May ...28 thg 9, 2023 ... BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to ...

Stock Price Forecast The 1 analysts offering 12-month price forecasts for Transcode Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00.Nov 24, 2023 · Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules GlobeNewswire Nov 30, …4 giờ trước ... BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to ...

TransCode Therapeutics Announces 1-for-20 Reverse Stock Split BOSTON, May 22, 2023 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors approved a 1-for-20 reverse stock ...26 thg 9, 2023 ... Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today? · TransCode Therapeutics (RNAZ) stock is dropping after announcing a public offering.The TransCode Therapeutics, Inc. stock price gained 6.25% on the last trading day (Wednesday, 22nd Nov 2023), rising from $0.230 to $0.245. During the last trading day the stock fluctuated 13.64% from a day low at $0.220 to a day high of $0.250. The price has fallen in 7 of the last 10 days and is down by -36.25% for this period.Designed to demonstrate delivery of TTX-MC138 to metastatic lesionsBOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more ...

TransCode Therapeutics, Inc. BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively ...

TransCode Therapeutics ( NASDAQ: RNAZ) Thursday announced the commencement of an underwritten public offering of shares of its common stock. In addition, the company said it expects to grant the ...

RNAZ's stock price has decreased by -97.55% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 1 stock analyst, the 12-month stock price forecast for RNAZ stock stock is $3.00, which predicts an increase of 1,150.52%.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including ...TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient ...WATERTOWN, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $175 million of …Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively ...Transcode Therapeutics Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-5.570 per share for the current fiscal year. Transcode Therapeutics Inc does not currently pay a dividend.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

TransCode Therapeutics stock skyrockets on positive brain cancer trial results. Proactive Investors • 09/25/23. TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138. GlobeNewsWire • …TransCode Therapeutics, Inc. 0.3599. +0.0338. +10.36%. BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed ...Oct 27, 2023 · TransCode Therapeutics stock is dropping alongside public offering plans.; The company hasn’t revealed the terms of the public offering just yet. That means traders still don’t know how many ... BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA ...52-week price history of RNAZ Stock. A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. TransCode Therapeutics Inc’s current trading price is -99.06% away from its 52-week high, while its distance from the 52-week low is 46.59%.According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each. This has the company expecting to raise $8 million in gross proceeds from the ...PTC Therapeutics (NASDAQ: PTCT) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with ...

TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full article TransCode Therapeutics, Inc.The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of TransCode Therapeutics, Inc. (NASDAQ:RNAZ), that sends ...Find the latest TransCode Therapeutics Inc (RNAZ) discussion and analysis from iHub's community of investors.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Sep 28, 2023 · AboutTransCodeTherapeutics. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of ... TransCode Therapeutics, Inc. 0.2328. -0.0071. -2.96%. BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed ...BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. RNAZ (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 5,000,000 shares of common …See the latest TransCode Therapeutics Inc stock price (RNAZ:XNAS), related news, valuation, dividends and more to help you make your investing decisions.According to the issued ratings of 1 analysts in the last year, the consensus rating for TransCode Therapeutics stock is Buy based on the current 1 buy rating for RNAZ. The average twelve-month price prediction for TransCode Therapeutics is $12.00 with a high price target of $12.00 and a low price target of $12.00.TransCode Therapeutics stock was trading sharply higher on Sept. 22. Why is RNAX stock going up and what’s the forecast for the stock? By Mohit Oberoi, CFA. Sep. 23 2021, Published 12:02 p.m. ET ...BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating ...

Further Supports TTX-MC138 Application in Brain Cancer. BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX …

TransCode expects that its cash of approximately $5.0 million as of December 31, 2022, together with approximately $1.3M in net proceeds received from the sale of common stock in its February 2023 registered direct offering and $871 thousand of additional funding expected in the second quarter of 2023 for the third year of its SBIR award will ...

Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per ...TransCode Therapeutics Market Cap: 697.84K, Enterprise value: N/A, P/E: -0.34, PEG ratio: N/A, EPS: -6.95, Revenue: N/A, EBITDA: -18.29M, Income: -31.18M, ...TransCode Therapeutics, Inc.: TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules 3 GlobeNewswire (USA)How to Buy Stock in Transcode Therapeutics · Decide where to buy Transcode Therapeutics stock · Open your brokerage account · Deposit funds into your brokerage ...Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. Nov. 23: CI TransCode Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 14: CI22 thg 5, 2023 ... (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, ...--TransCode Therapeutics, Inc.,, an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an underwritten public offering ...8 thg 7, 2021 ... The shares are expected to begin trading on the Nasdaq Capital Market on July 9, 2021 under the symbol “RNAZ.” The offering is expected to close ...TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update. ... The purchase of each share of common stock or PFW was accompanied by one Series A-1 warrant and one Series A-2 warrant. The Series A warrants are exercisable for three years at an exercise price of $3.25 per share. Net proceeds …In connection with the reverse stock split, the Company's CUSIP number will change to 89357L 204 as of 4:05 pm on Monday, May 22, 2023. About TransCode Therapeutics

Nov 24, 2023 · Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. TransCode Therapeutics Inc. Watch list NEW Set a price target alert Open Last Updated: Nov 30, 2023 2:35 p.m. EST Real time quote $ 0.3328 0.0838 33.65% Previous Close $0.2490 Advanced Charting... BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively treating cancer using RNA therapeutics, today ...Instagram:https://instagram. irsxmsn stocks marketaditxt stockbee stock TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full article TransCode Therapeutics, Inc.Complete TransCode Therapeutics Inc. stock information by Barron's. View real-time RNAZ stock price and news, along with industry-best analysis. how much is 1943 pennyairline stock prices today --TransCode Therapeutics ... it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of ...May 22, 2023 · The 1-for-20 reverse stock split will automatically convert 20 current shares of TransCode’s common stock into one new share of common stock. No fractional shares will be issued in connection ... best mobile banking application TransCode Therapeutics Withdraws Public Offering (GlobeNewswire) +10.36% Oct-27-23 08:16AM Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today? (InvestorPlace) -21.61% 08:00AM Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to ConditionsNov 24, 2023 · Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. TransCode Therapeutics, Inc. 0.3599. +0.0338. +10.36%. BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed ...